Ring Therapeutics has harnessed the commensal virome with the creation of a novel class of gene therapy vectors, known as Anellovectors. In this work, we present considerations for downstream purification of this novel class of gene therapy vectors ranging from harvest, chromatog., and TFF unit operations.